News & Media

Events
Interim Report January - September 2019

Read more
Events
Interim Report January - June 2019

Read more
Events
BIO International Convention

Read more
Events
2019 ASCO Annual Meeting in Chicago, USA

Read more
Events
Redeye Pre-ASCO Seminar

Read more
Press release
New data from the phase I study of birinapant in combination with Keytruda® will be presented at the ASCO 2019

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today informs that new data from the phase I study of birinapant in...

Read more
Press release
Positive data from the remetinostat phase II study in basal cell carcinoma presented at SID Annual meeting

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that positive data from the investigator-initiated study evaluating the effects of...

Read more
Press release
Resolutions at the Annual General Meeting in Medivir on 9 May 2019

Approval of profit and loss accounts and balance sheets, and discharge from liability of the board members and the managing directorThe...

Read more
Press release
Data from the remetinostat phase II study in basal cell carcinoma patients to be presented at the 2019 SID Annual meeting

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that data from the investigator-initiated study evaluating the effects of remetinostat...

Read more
Press release
Safety and efficacy data from the MIV-711 phase II open label extension study presented at the OARSI world congress

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today informs that new data from the phase II program of MIV-711, has...

Read more
Press release
MEDIVIR AB – INTERIM REPORT, JANUARY – MARCH 2019

Clinical studies progress according to plan January – MarchSignificant events during the quarter The phase II study of birinapant in combination...

Read more
Events
Interim Report January - March 2019

Read more